SCYNEXIS, Inc. Number of Reportable Segments
SCYNEXIS, Inc. (SCYX) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-10
- SCYNEXIS, Inc. number of reportable segments for the quarter ending 2026-03-31 was 1.00 Segment, a 0.00% change year-over-year.
- SCYNEXIS, Inc. number of reportable segments for the quarter ending 2025-03-31 was 1.00 Segment.
- SCYNEXIS, Inc. number of reportable segments for fiscal 2025 was 1.00 Segment.
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-04 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | 1.00 Segment 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | 1.00 Segment 10-Q · filed 2025-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |